Key Points
- Chief Financial Officer Christopher Ryan Sullivan sold 7,979 shares on April 1 at an average of $16.77 (~$133,808) and 7,980 shares on April 2 at $17.15 (~$136,857) under a pre-arranged Rule 10b5-1 trading plan, leaving him with 25,318 shares — a ~23.96% reduction in his direct ownership.
- Avalo Therapeutics (NASDAQ: AVTX) is trading in the mid-teens (opened $17.76) with a market cap of about $404.8M and a 52-week range of $3.39–$20.72; analysts hold a consensus Moderate Buy with a $42.25 target and the company recently posted an EPS beat for the quarter.
Avalo Therapeutics, Inc. (NASDAQ:AVTX - Get Free Report) insider Mittie Doyle sold 679 shares of the business's stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $16.00, for a total transaction of $10,864.00. Following the completion of the transaction, the insider directly owned 3,622 shares in the company, valued at $57,952. This trade represents a 15.79% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Mittie Doyle also recently made the following trade(s):
- On Monday, March 16th, Mittie Doyle sold 25,492 shares of Avalo Therapeutics stock. The stock was sold at an average price of $16.15, for a total transaction of $411,695.80.
Avalo Therapeutics Stock Performance
AVTX opened at $17.76 on Friday. The stock has a market capitalization of $404.75 million, a price-to-earnings ratio of -3.10 and a beta of 0.93. The company has a fifty day moving average of $15.54 and a 200 day moving average of $15.96. Avalo Therapeutics, Inc. has a fifty-two week low of $3.39 and a fifty-two week high of $20.72.
Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) last announced its quarterly earnings results on Monday, March 23rd. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($1.54) by $1.17. The company had revenue of $0.06 million during the quarter, compared to analysts' expectations of ($0.21) million. On average, equities research analysts forecast that Avalo Therapeutics, Inc. will post -19.07 earnings per share for the current year.
Institutional Inflows and Outflows
Hedge funds have recently bought and sold shares of the company. Orbimed Advisors LLC raised its stake in shares of Avalo Therapeutics by 39.5% in the third quarter. Orbimed Advisors LLC now owns 1,349,300 shares of the company's stock valued at $17,150,000 after acquiring an additional 382,300 shares during the period. Nantahala Capital Management LLC boosted its stake in shares of Avalo Therapeutics by 24.1% during the 3rd quarter. Nantahala Capital Management LLC now owns 1,235,000 shares of the company's stock worth $15,697,000 after purchasing an additional 240,000 shares during the period. Affinity Asset Advisors LLC boosted its stake in shares of Avalo Therapeutics by 4.5% during the 4th quarter. Affinity Asset Advisors LLC now owns 1,051,054 shares of the company's stock worth $19,087,000 after purchasing an additional 44,837 shares during the period. Caligan Partners LP grew its holdings in Avalo Therapeutics by 5.8% during the 4th quarter. Caligan Partners LP now owns 881,533 shares of the company's stock valued at $16,009,000 after purchasing an additional 48,200 shares during the last quarter. Finally, Balyasny Asset Management L.P. purchased a new stake in Avalo Therapeutics in the 3rd quarter worth about $10,390,000. Institutional investors own 87.06% of the company's stock.
Analyst Upgrades and Downgrades
A number of brokerages recently commented on AVTX. Weiss Ratings reissued a "sell (d-)" rating on shares of Avalo Therapeutics in a research note on Friday, January 9th. Guggenheim assumed coverage on Avalo Therapeutics in a research note on Monday, February 2nd. They issued a "buy" rating and a $50.00 price objective on the stock. Mizuho upgraded Avalo Therapeutics to a "strong-buy" rating in a research report on Thursday, December 18th. BTIG Research reiterated a "buy" rating and set a $40.00 target price on shares of Avalo Therapeutics in a research report on Tuesday, March 24th. Finally, HC Wainwright raised their target price on shares of Avalo Therapeutics from $25.00 to $40.00 and gave the company a "buy" rating in a report on Wednesday, March 25th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Avalo Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $42.25.
Get Our Latest Report on Avalo Therapeutics
Avalo Therapeutics Company Profile
(
Get Free Report)
Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company's proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.
Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
